X

Trial Profile

A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atuliflapon (Primary) ; Dapagliflozin
Indications Renal failure
Focus Therapeutic Use
Acronyms FLAIR
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

07 Dec 2023 Status changed from completed to discontinued.
05 Oct 2022 Status changed from active, no longer recruiting to completed.
23 Sep 2022 This trial has been Completed in Hungary, according to European Clinical Trials Database record.(Global end date 06/09/2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com